Pumacayo-Cárdenas SC, Chino-Mendoza JM, de la Torre-Gascón A, Meave-González A

Language: Spanish
References: 13
Page: 142-147
PDF size: 1486.37 Kb.

ABSTRACT

Background: Gadobutrol is a gadolinium-based contrast agent, its safety is well known, there are no previous reports exploring the safety and tolerability of gadobutrol in Mexican population. Objective: Assess the incidence of acute adverse drug reactions (ADR) due to administration of gadobutrol in patients who were submitted to MRI. Patients and methods: Design was observationat retrospective, transverse. We analyzed a database of 705 patients, from 12 to 89 years old sent to MRI using gadobutrol, from April to September 2018 at the "Instituto de Nacional de Cardiología Ignacio Chavez, México". Results: Eighteen patients (2.55%) presented ADR to gadobutrol predominantly in males (66%). We found a higher incidence in the age range from 21-40 years. The body mass index was normal in most of the patients. The average dose of gadobutrol was 0.12 mmol/kg, the average of the total dose was 9.35 ml, the mean injection rate was 2.38 ml/s. The ADR were predominantly mild (mainly nausea and vomit, 2% of the studied population and 77% of the total ADR). No severe ADR were reported. Conclusions: Mild ADR were more prevalent in Mexican population compared to previous reports, we found they are presented more frequently, almost 10 times more than it was described in other larger registries.

REFERENCES

1. Committee on Drugs and Contrast Media, American College of Radiology. ACR Manual on Contrast Media. Version 10.3. ACR; 2018.

2. Scott LJ. Gadobutrol: a review of its use for contrasHnhanced magnetic resonance imaging in adults and children. Clin Drug Investig. 2013;33:303-14.

3. Saake M, Langner S, Schwenke C, Weibart M, Jansen O, Hosten N, et al. MR1 in multiple sclerosis: an intra- individual, randomized and multicentric comparison of gadobutrol with gadoterate meglumine at 3 T. Eur Radio!. 2016;26:820-8.

4. Nelson KL, Gifford LM, Lauber-Huber C, Gross CA, Lasser TA. Clinical safety of gadopentetate dimeglumine. Radiology. 1995;196(2):439-43.

5. Weber J. Epidemiology of adverse reactions to nonsteroidal antiinflammatory drugs. En: Rainsford K, Velo G, editores. Advances in inflammation research, vol. 6. New York: Raven Press, Ltd; 1984.

6. Forsting M, Palkowitsch P. Prevalence of acute adverse reactions to gadobutrol. A highly concentrated macrocyclic gadolinium chelate: Review of 14,299 patients from observational trials. Eur J Radio!. 2010;74:186-92.

7. Prince M, Lee HG, Lee CH, Youn SW, Lee IH, Yoon W, Yang B, et al. Safety of gadobutrol in over 23,000 patients: the GAROIAN study, a global multicentre, prospective, non-interventional study. Eur Radio!. 2017;27:286-95.

8. Glutig K, Bhargava R, Hahn G, Hirsch W, Kunze C, Mentzel HJ, et al. Safety of gadobutrol in more than 1,000 pediatric patients: subanalysis of the GAROIAN study, a global multicenter prospective non-interventional study. Pediatr Radio! 2016;46:1317-23.

9. Power S, Talbot N, Kucharczyk W, Mandell OM. Allergic-like Reactions to the MR Imaging Contrast Agent Gadobutrol: A Prospective Study of 32 991 Consecutive lnjections. Radiology. 2016;281:72-7.

10. Shen Y, Goemer FL, Snyder C, Morelli JN, Hao O, Hu O, et al. T1 relaxivities of gadolinium-based magnetic resonance contrast agents in human whole blood at 1.5, 3, and 7 T. Invest Radio!. 2015;50:330-8.

11. Forghani R. Adverse Effects of Gadolinium-Based Contrast Agents: Changes in Practice Pattems. Top Magn Reson Imaging. 2016;25:163-9.

12. Scott LJ. Gadobutrol: A Review of Its Use for Contrast-Enhanced Magnetic Resonance Imaging in Adults and Children. Clin Drug Investig 2013;33: 303-14.

13. Rozenfeld M, Podberesky N. Gadolinium-based contrast agents in children. Pediatr Radio!. 2018;48:1188-96.